One-Shot gene injection tested for rare blinding eye conditions
NCT ID NCT07185256
Summary
This early-stage study is testing a one-time gene therapy injection called OPGx-BEST1 for two rare, inherited eye diseases (BVMD and ARB) that cause vision loss. The main goal is to check the safety and side effects of the treatment and find the best dose. Researchers will follow 10 adult patients for 5 years after a single injection into one eye to see if it helps control the disease and preserve vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital Los Angeles
RECRUITINGLos Angeles, California, 90027, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cincinnati Eye Institute
RECRUITINGCincinnati, Ohio, 45242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Retina Foundation of the Southwest
RECRUITINGDallas, Texas, 75231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vitreo Retinal Associates
NOT_YET_RECRUITINGGainesville, Florida, 34481, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.